基于微信公开账户,对乳腺癌不同治疗方案的信息的比较可读性
Bingyan Li1, Jia Liu2, Yuxi Zhang2
1The First Affiliated Hospital of Anhui Medical University, Hefei, China.
PloS one
|January 24, 2025
概括
在微信公众账户上关于乳腺癌治疗的信息的可读性很低,特别是医疗选择. 为了更好的公众理解,需要改进内容和参与度.
科学领域:
- 在瘤学瘤学.
- 卫生沟通健康沟通
- 数字健康数字健康
背景情况:
- 微信公众账户是公众健康信息的重要来源.
- 了解这些平台上的乳腺癌治疗信息的可读性对于患者教育至关重要.
研究的目的:
- 在微信上评估和比较乳腺癌治疗信息的可读性.
- 提出提高这些信息的清晰度和可访问性的策略.
- 为微信上的内容创作者提供指导.
主要方法:
- 在2021年4月使用Sogou在微信上搜索乳腺癌文章.
- 包括37个精选的公共账户中的四篇最新文章,提供乳腺癌信息.
- 使用材料适用性评估 (SAM) 工具评估可读性,比较手术,医学,补充和替代医学 (CAM) 和综合治疗.
主要成果:
- 总共分析了136篇文章,中位数的SAM分数表明可读性低于理想.
- 与医疗和手术治疗相比,补充和替代医学 (CAM) 文章在内容,学习刺激和文化适当性方面得分更高.
- 在文化适应性方面,CAM文章的可读性也比综合性文章更高.
结论:
- 在微信公开账户上,乳腺癌治疗信息的整体可读性不足.
- 医疗治疗信息,特别是临床试验细节,需要在内容,视觉和参与策略方面大幅度改进.
- 提高可读性至关重要,以确保公众能够有效地理解和利用乳腺癌治疗信息.
更多相关视频
12:35Comparison of Three Different Methods for Determining Cell Proliferation in Breast Cancer Cell Lines
Published on: September 3, 2016
19.4K
13:35Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
2.4K
相关概念视频
Cancer Survival Analysis
327
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
327
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Comparing the Survival Analysis of Two or More Groups
140
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
140
Hazard Ratio
81
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
81
